Practice Areas

Print PDF

Amgen v Sandoz: The Biosimilars Saga Continues

October 27, 2015
Life Sciences IP Review
Autumn 2015

Despite the US Court of Appeals for the Federal Circuit's ruling in Amgen v Sandoz, significant uncertainty concerning two key provisions of the BCPIA remains, as Pharmaceutical Practice Group  Co-Chairs Steve Coyle and Leslie-Anne Maxwell describe in their article, "Amgen v Sandoz: The Biosimilars Saga Continues" published in Life Sciences IP Review, Autumn 2015 issue.


View Document(s):